IOVANCE BIOTHERAPEUTICS, INC. Debt Securities, Available-for-sale, Noncurrent
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Debt Securities, Available-for-sale, Noncurrent of $27.70 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2023-02-28
- 2022-03-31: Debt Securities, Available-for-sale, Noncurrent $27.70M.
- 2021-12-31: Debt Securities, Available-for-sale, Noncurrent $91.59M.
- 2021-09-30: Debt Securities, Available-for-sale, Noncurrent $78.25M.
- 2021-06-30: Debt Securities, Available-for-sale, Noncurrent $46.29M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2022-03-31 | $27.70M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $91.59M 10-K · filed 2023-02-28 |
| 2021-09-30 | $78.25M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $46.29M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $10.23M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |